Articles by Joe Galati
05.12.23 -- Project Orbis For Cell & Gene Therapies Gathers Momentum
By Jessie Hanrahan, Solid Biosciences Project Orbis has worked very well for oncology products. CBER Director Dr. Peter Marks recently started promoting the development of a similar program, which would coordinate review with other regulators, for cell and gene therapies. This would be an enormous step forward.
09.01.22 -- Continuous Manufacturing: What's The Environmental Impact?
By John F. Kokai-Kun, USP Part 1 of this two-part series began to compare the environmental impact of biopharma continuous manufacturing with batch manufacturing. In this article, the author considers process efficiency, single-use technology, and facilities requirements.
Safety First: Controlling Occupational Exposure In Oncology Drug Development
By Joe Galati, PhD, Sr. Director, Global Toxicology Services, Thermo Fisher Scientific Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs, targeted therapeutics that zero in on specific parts of cancer cells while sparing normal cells have become mainstream cancer treatments. Delivering on the potential of small molecule oncology therapies requires understanding and embracing safe handling practices and containment technology.
Safety First: Controlling Occupational Exposure In Oncology Drug Development
By Joe Galati, PhD, Sr. Director, Global Toxicology Services, Thermo Fisher Scientific Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs, targeted therapeutics that zero in on specific parts of cancer cells while sparing normal cells have become mainstream cancer treatments. Delivering on the potential of small molecule oncology therapies requires understanding and embracing safe handling practices and containment technology.
Safety First: Controlling Occupational Exposure In Oncology Drug Development
By Joe Galati, PhD, Sr. Director, Global Toxicology Services, Thermo Fisher Scientific Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs, targeted therapeutics that zero in on specific parts of cancer cells while sparing normal cells have become mainstream cancer treatments. Delivering on the potential of small molecule oncology therapies requires understanding and embracing safe handling practices and containment technology.
#COVID19 Update on Apple Podcasts
This week on Your Health First, Dr. Sam Pappas, an Internal Medicine physician in Northern Virginia, talks with Dr. Galati about the latest in Covid-19 care. Since the start of the pandemic, Dr. Pappas has been aggressive in managing his outpatients with Covid-19, making use of a wide variety of therapies.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Joe
Contact Joe, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack